Jus-InvestorsTM
About Us
JusGlobal removes such risks and accelerates innovation while increasing fundamentals such as safety, accuracy, quality control, communications and risk management. JusGlobal is delivered by a multi-industry team each performing at the top of their respective professions -- and nearly all command an unrivaled understanding of the vicissitudes of the current world business market, given their extensive international experience.
The JusGlobal Advisory Board united with Chairman O’Brien is the team that protects corporate boards of directors and individual shareholders as well as venture capitalists; and we provide full support to the executive management and product development teams of our clients. The patented JusGlobal platform introduces solutions that can rapidly generate market growth, attract increased investor interest or position a company for a profitable merger or acquisition.
The JusGlobal Apps
JusGlobal is a team of innovators who are applying their industry insights to introduce revolutionary processes to the world of business that can preserve billions in budgetary capital through optimal asset allocation.
JusGlobal enables clients to introduce their products and services in less time, disrupting competition and accelerating profit and ROI.
We’ve already achieved in delivering a groundbreaking innovation in access to law firm services for every type of client the world over; and our clinical trials guidance and technology will save the pharmaceutical, biotechnology and medical devices industries billions in development costs while advancing the speed of profit.
Our Jus-Health transforms health care delivery to ease patient burdens and inconveniences while boosting the financial balance sheet for physician and hospital groups as well as retail pharmacies. And we won’t ever rest when it comes to applying our capabilities to protect investors – we’re growing our highly credentialed team every day and delivering industry-changing insights that will alter the landscape of business at the intersection of quality, security, safety and profitability.
JusGlobal Empowers Organizations
As JusGlobal, we set out to challenge and resolve current faltering ways of executing business. JusGlobal empowers organizations to excel in their passions and deliver best-in-class products and services quicker and more efficiently, which leads to healthy ROI.Protect & Reward Investors
Wether a multinational corporation seeking to further international commerce, or a small company with a niche product that would like to attract acquisition interest, JusGlobal can introduce the exact solutions to accomplish business goals, and protect and reward investors.Introduce JusGlobal to Your Investment Enterprise
JusGlobal wants to hear from investors.
We are happy to meet with Boards of Directors, attend shareholder meetings and introduce our innovations to your executive management team.We have access to the most elite thought leaders traversing global industry -- and we can deliver such teams to any investor-centric organization by offering customized solutions that upend industry status quo while elevating brand value.
JusGlobal can transform virtually any organization with a precise solution for the business challenges that threaten corporate valuation, stock price and market position.
JusGlobal wants to hear from venture capitalists. We advise on decisions regarding investment, capital deployment and operational efficiencies. We foster promising concepts into marketplace revolutions
Click Here
Contact us to begin a conversation that will optimize your ROI. JusGlobal wants to hear from venture capitalists. We advise on decisions regarding investment, capital deployment and operational efficiencies. We foster promising concepts into marketplace revolutions.
Optimize your ROIClick Here
Advance a discussion about JusGlobal services for start up innovators and expanding enterprises.
Innovate & ExpandOur Jus-Investors Team
Jus-Investors is led by Founder, Chairman & CEO Beatrice O’Brien whose vision to combine highest credentialed industry-specific advisory with groundbreaking sector-specific technology has created a revolution that will forever enhance productivity, profitability and market valuation of organizations across myriad verticals.
CEO O’Brien leads a veritable Wall Street of accomplished corporate strategists, international executives, management consultants, attorneys and regulatory authors who form the Jus-Investors Advisory Board. With access to unparalleled global talent, Jus-Investors can offer unprecedented industry intelligence to create powerful solutions that improve performance, catapult profits and maintain market credibility -- the pillars of sound investment.
Beatrice O'Brien
FOUNDER/CHAIR/CEO
Beatrice O’Brien brings immeasurable value to JusLaw, not just her passion for the Law and the Legal Industry but also her over 20 years of legal experience with Wall Street Firms, such as, Cadwalder Wickersham & Taft and with international firms in Australia and the UK.
She has worked with high profile clients, such as, Warren Buffet and on high-profile cases, such as, the largest reorganization and restructuring cases in US, UK, and Australian corporate history.
Beatrice is a graduate of Bond University the only Private Law School in Australia with a Law Degree and is a graduate of Harvard Law School Executive Program. She speaks fluent Hindi. Beatrice leveraged her extensive experience to create the first of its kind marketplace revolutionizing the legal industry.
John C. Ferrara
ADVISORY BOARD
John C. Ferrara is on the Advisory Board of JusLaw with extensive experience in corporate governance, business strategy, finance, operations, business development, capital raising, risk management, cash management, M&A and company exits.
John has served on the Boards of four (4) public companies; including GAMCO Investors, Inc. (NYSE:GBL) and has been the CFO of several public companies; including The Street Inc. (NASDAQ:TST), EDGAR Online, Inc.(NASDAQ:EFGR) and Renaissance Communications Corp. (NYSE:RRR).
John has over twenty years of C-level experience at public, private and PE portfolio entrepreneurial companies; including start-ups, turnarounds, and high growth organizations, with a prior background at two Fortune 500 corporations (NBC & American Express) and a Big 4 public accounting firm (Deloitte).
Oliver Ramsbottom
ADVISORY BOARD MEMBER
Partner with McKinsey & Company for over 20 years, based out of Hong Kong & Tokyo. Oliver brings to JusLaw over 20 years international experience in strategy and business development and start-ups. He is a graduate of Oxford & Harvard Business School.
Mr. Ramsbottom speaks fluent Mandarin.
Duane Lakings delivers a broad array of expertise in various primary areas of drug discovery and development to the JusGlobal enterprise. Dr. Lakings is experienced across nonclinical pharmacology, pharmacokinetics and toxicology as well as clinical safety, efficacy, chemistry, manufacturing and control of drug substances and proposed drug products and regulatory affairs. He assists pharmaceutical and biotechnology companies in evaluating results from their drug discovery and development programs, including document preparation, protocol design and implementation across multiple disciplines, as well as further evaluation of drug candidates to support regulatory submission.
Dr. Lakings has served as president of Texas-based Drug Safety Evaluation and was director of drug safety evaluations at Regeneron Pharmaceuticals in Tarrytown, New York as well as a senior research investigator II at BMS-PRI (Princeton, NJ). He has been a research scientist at The Upjohn Company in Michigan and he has conducted research for the National Cancer Institute and the University of Missouri-Columbia.
Dr. Lakings has extensive publishing credits. He has authored or co-authored 44 refereed papers and 150 company-specific papers, nine book chapters on drug development, 26 abstracts for oral/poster presentation, eight commissioned drug candidate evaluation reviews and a 300-page report on biological contract research organizations (CROs).
Dr. Eyal Ron adds value for Jus Pharma clients in the pharmaceutical, biotechnology and medical device space by accelerating the timeline toward the value inflection point. Dr. Ron delivers an entrepreneurial thought process coupled with science-based evaluation to enhance the overarching enterprise value regarding product candidates, without creating a need for costly infrastructure to foster growth.
With three decades of experience in the development of drugs, biomaterials, devices and drug delivery systems, Dr. Ron has become known for combining science with sound business strategy, making him an ideally qualified expert on the JusGlobal team. He developed and implemented the scientific, regulatory and clinical strategy for several companies. Dr. Ron offers extensive depth in the total therapeutic development process including project management, clinical trials, regulatory compliance and approval, drug delivery systems, quality control and scale-up. Dr. Ron has authored more than 100 papers, book chapters and abstracts. He is also the inventor of 50 patents, principally in drug formulations, drug delivery, tissue engineering and biomaterials.
He has been a founder or principal formulator of biotech companies, bringing seven new medications to market. He has held the position of COO, CTO and CSO, director of pharmaceutical development and principal investigator at several pharmaceutical and biotech firms.
Dr. Ron received a PhD from Brandeis University and has completed post graduate study at Massachusetts Institute of Technology. He earned a BS at Tel Aviv University.
Jack Habert
Senior Vice President at Investment Bank Jeffries Group LLC based in New York. Jack brings to JusLaw expertise in the legal requirements for online platform businesses having been advisor to government entities including the Securities and Exchange Commission (SEC) and the Commodities Futures Trading Commission (CFTC) on the development of new legal regulation.
Jack experience expands also to his practice of law for AM LAW 100 Firm, Willkie Farr Gallagher bringing high caliber legal network to JusLaw platforms.
Jason Stiehl
Partner Loeb & Loeb LLP based in New York. Jason brings to JusGlobal a large legal network across consumer class defenses as well as corporate espionage litigation and consulting. He was named a “Best Lawyer” in 2021 Trade Secrets Law: The Best Lawyers in America.
Dona Zimmerman
ADVISORY BOARD MEMBER
Dona has over 30 years in the legal education industry. She was co-founder and vice president of PMBR, a national preparation course for the Multistate Bar Examination which she sold to Kaplan in 2006 for over 200m. Dona is currently the Founder and President of Your Bar Exam Tutor.com. Being a renowned authority on legal education, Dona brings to JusLaw a broad view of the legal industry and legal education to JusLaw.
Dr. Evan Siegel, Ph.D.
CHIEF REGULATORY OFFICER
Dr. Evan Siegel adds value for Jus- Pharma clients in the pharmaceutical, biotechnology and medical device space in the Regulatory Affairs and Product Development.
Dr. Siegel served as Chief Executive Officer of OXO Chemie Inc. from 1997 to 1999. Before he joined OXO Chemie, he was the Vice President, Regulatory Affairs and Bioethics for Medical Science Systems, Inc. Prior to that he was Director of Regulatory Consulting Services and Principal Regulatory Scientist for Quintiles, Inc., in Research Triangle Park, North Carolina. He has served in regulatory affairs and executive positions in the pharmaceutical (Astra, Syntex, and OXO Chemie), Genetics Testing Industries (Medical Science Systems); and trade association environments.
Dr. Siegel has also held positions as a Toxicology Reviewer at the US Food and Drug Administration and California Department of Health Services and, at the latter, was Chief of Special Services.
He attended Bucknall University where he received a Bachelor’s of Science degree in Physics; Rutgers University, where he earned a Masters of Science degree in Radiological Health/Health Physics; the Waksman Institute of Microbiology where he earned both his Masters and Doctor of Philosophy degrees in Virology and Molecular Biology, and was awarded Postdoctoral Fellowships in Medical Genetics and Genetics Counselling at the University of North Carolina at Chapel Hill.
Dr. Siegel is an Adjunct Professor at the University of Queensland and the Centre for the Study of Preclinical Drug Development, Brisbane, Australia, and a member of the California Lieutenant Governor’s Biotechnology Advisory Group to the California Council for Economic Development.
Patricia Blaine is a registered respiratory therapist, university instructor and accomplished medical writer. She has served as a consultant in clinical trial protocols for leading pharmaceutical companies such as Eisai, Daiichi Sankyo, Forest Laboratories and Schering-Plough.
Ms. Blaine has been a senior director of medical writing and a staff medical writer for Oxford Research, Corning-Besselaar and Schering-Plough. She has been director of clinical education at the University of Medicine and Dentistry of New Jersey (UMDNJ). Ms. Blaine provided medical writing for a poster presented at a psychiatric conference focusing on a Phase IV multi-site investigatory study on carmbamazepine.
Patricia Blaine earned a Master’s degree in Education with a concentration in Allied Health Education from Rutgers University and a Bachelor of Arts in Psychology and English from Seton Hill University (Pennsylvania).
Jus-InvestorsTM